Tribulus terrestris for treatment of sexual dysfunction in women: randomized double-blind placebo - controlled study

Elham Akhtari, Firoozeh Raisi, Mansoor Keshavarz, Hamed Hosseini, Farnaz Sohrabvand, Soodabeh Bioos, Mohammad Kamalinejad, Ali Ghobadi, Elham Akhtari, Firoozeh Raisi, Mansoor Keshavarz, Hamed Hosseini, Farnaz Sohrabvand, Soodabeh Bioos, Mohammad Kamalinejad, Ali Ghobadi

Abstract

Background: Tribulus terrestris as a herbal remedy has shown beneficial aphrodisiac effects in a number of animal and human experiments. This study was designed as a randomized double-blind placebo-controlled trial to assess the safety and efficacy of Tribulus terrestris in women with hypoactive sexual desire disorder during their fertile years. Sixty seven women with hypoactive sexual desire disorder were randomly assigned to Tribulus terrestris extract (7.5 mg/day) or placebo for 4 weeks. Desire, arousal, lubrication, orgasm, satisfaction, and pain were measured at baseline and after 4 weeks after the end of the treatment by using the Female Sexual Function Index (FSFI). Two groups were compared by repeated measurement ANOVA test.

Results: Thirty women in placebo group and thirty women in drug group completed the study. At the end of the fourth week, patients in the Tribulus terrestris group had experienced significant improvement in their total FSFI (p < 0.001), desire (p < 0.001), arousal (p = 0.037), lubrication (p < 0.001), satisfaction (p < 0.001) and pain (p = 0.041) domains of FSFI. Frequency of side effects was similar between the two groups.

Conclusions: Tribulus terrestris may safely and effectively improve desire in women with hypoactive sexual desire disorder. Further investigation of Tribulus terrestris in women is warranted.

Figures

Figure 1
Figure 1
Flow chart indicating subject enrolment, group allocation and analysis according to CONSORT guidelines.

References

    1. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol. 2008;112(5):970–978. doi: 10.1097/AOG.0b013e3181898cdb.
    1. Leiblum SR, KKoochaki PE, Rodenberg CA, Barton IP, Rosen RC. Hypoactive Sexual desire disorder in postmenopausal women: US results from the Women’s International Study of Health and Sexuality (WISHeS) Menopause. 2006;13(1):46–56. doi: 10.1097/01.gme.0000172596.76272.06.
    1. Dennerstein L, Koochaki P, Barton I, Graziottin A. Hypoactive sexual desire disorder in menopausal women: a survey of western European women. J Sex Med. 2006;3(2):212–22. doi: 10.1111/j.1743-6109.2006.00215.x.
    1. Hayes RD, Dennerstein L, Bennett CM, Fairley CK. What is the “true” prevalence of female sexual dysfunctions and does the way we assess these conditions have an impact? J Sex Med. 2008;5(4):777–778. doi: 10.1111/j.1743-6109.2007.00768.x.
    1. Safarinejad MR. Female sexual dysfunction in population based study in Iran: prevalence and associated risk factors. Int J Impot Res. 2006;18(4):382–395. doi: 10.1038/sj.ijir.3901440.
    1. Davis SR, van der Mooren MJ, van Lunsen RH, Lopes P, Ribot J, Rees, Moufarege A, Rodenberg C, Buch A, Purdie DW. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause. 2006;13(3):387–396. doi: 10.1097/01.gme.0000179049.08371.c7.
    1. Berman JR, Berman LA, Werbin TJ, Goldstein I. Female sexual dysfunction: anatomy, physiology, evaluation and treatment options. Curr Opin Urol. 1999;9(6):563–568. doi: 10.1097/00042307-199911000-00012.
    1. Segraves RT, Clayton A, Croft H, Wolf A, Wamock J. Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women. J Clin Psychopharmacol. 2004;24(3):339–342. doi: 10.1097/01.jcp.0000125686.20338.c1.
    1. Kashani L, Raisi F, Saroukhani S, Sohrabi H, Modabbernia A, Nasehi AA, Jamshidi A, Ashrafi M, Mansouri P, Ghaeli P, Akhondzadeh S. Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study. Hum Psychopharmacol. 2013;28(1):54–60. doi: 10.1002/hup.2282.
    1. Simon JA. Opportunities for intervention in HSDD. J Fam Pract. 2009;58(7 Suppl Hypoactive):S26–30.
    1. Basson R, Leiblum S, Brotto L, Derogatis L, Fourcroy J, Fugl-Meyer K, Graziottin A, Heiman JR, Laan E, Meston C, Schover L, van Lankveld J, Schultz WW. Definitions of women’s sexual dysfunction reconsidered: advocating expansion and revision. J Psychosom Obstet Gynaecol. 2003;24(4):221–229. doi: 10.3109/01674820309074686.
    1. Clayton AH. The pathophysiology of hypoactive sexual desire disorder in women. International J of Gynecol Obstet. 2010;110(1):7–11. doi: 10.1016/j.ijgo.2010.02.014.
    1. Ibn-e-sina (Avicenna Husain) Al-Qanun fit-tib [The Canon of Medicine] Beirut, Lebanon: Alaalami Beirut library Press; 2005. ((Research of Ebrahim Shamsedine)).
    1. Aghili Khorasani MH. Makhzan al Advieh. Tehran, Iran: Bavardaran Press. Research Institute for Islamic and Complementary Medicine, Iran University of Medical Sciences; 2001.
    1. Mazaro-Costa R, Andersen ML, Hachul H, Tufik S. Medicinal plants as alternative treatments for female sexual dysfunction: Utopian vision or possible treatment in climacteric women? J Sex Med. 2010;7(11):3695–3714. doi: 10.1111/j.1743-6109.2010.01987.x.
    1. Esfandiari A, Dehghan A, Sharifi S, Vesali E. Effect of Tribulus Terresteris extract on ovarian activity in immature wistar rat: a histological evaluation. J Anim Vet Adv. 2011;7(10):883–886.
    1. Brotto LA. The DSM4 diagnostic criteria for hypoactiove sexual desire disorder in women. Arch Sex Behav. 2010;39(2):221–239. doi: 10.1007/s10508-009-9543-1.
    1. Zargari A. Medicinal plants, Vol 1; Tehran. Iran: Tehran University of Medical Sciences Press; 1989.
    1. Abirami P, Rajendran A. GC-MS analysis of Tribulus terrestris. 1. Asian J Plant Sci Res. 2011;1(4):13–16.
    1. Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross validation and development of clinical cutoff scores. J Sex Marital Ther. 2005;31(1):1–20. doi: 10.1080/00926230590475206.
    1. Rosen R, Brown C, Heiman J, Meston C, Shabsigh R, Ferguson D, Agostino R Jr. The female sexualfunction index (FSFI): a multidimensional self-report instrument of female sexual function. J Sex Marital Thera. 2000;26(2):191–208. doi: 10.1080/009262300278597.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する